EUVIMEDEUVIMED entdecken
KohortenstudieStudienprotokoll

Effectiveness of Vaccines and Monoclonal Antibodies Against Respiratory Syncytial Virus: Generic Protocol for Register-Based Cohort Study

Eero Poukka iD, Caren van Roekel, Topi Turunen iD, Ulrike Baum iD, Rolf Kramer iD, Elizabeth Begier iD, Lance Presser iD, Anne Teirlinck iD, Terho Heikkinen iD, Mirjam Knol, Hanna Nohynek, PROMISE Investigators

The Journal of Infectious Diseases · 2024

DOI: 10.1093/infdis/jiad484 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift The Journal of Infectious Diseases, 2024. Verfasst von Eero Poukka und 11 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Disease Control and Vaccinations Unit, Department of Health Security, Finnish Institute for Health and Welfare. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus, Human, Vaccines. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Several immunization products are currently being developed against respiratory syncytial virus (RSV) for children, pregnant females, and older adults, and some products have already received authorization. Therefore, studies to monitor the effectiveness of these products are needed in the following years. To assist researchers to conduct postmarketing studies, we developed a generic protocol for register-based cohort studies to evaluate immunization product effectiveness against RSV-specific and nonspecific outcomes. To conduct a study on the basis of this generic protocol, the researchers can use any relevant databases or healthcare registers that are available at the study site.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Syncytial Virus, HumanVaccinesChildFemalePregnancyHumansAgedAntibodies, MonoclonalCohort StudiesVaccinationDrugs, Generic

Stichwörter der Autor:innen

RSVmaternal immunizationmonoclonal antibodyrespiratory syncytial virusvaccine

Substanzen

Antibodies, MonoclonalVaccinesDrugs, Generic

Autor:innen und Institutionen

  • Infectious Disease Control and Vaccinations Unit, Department of Health Security, Finnish Institute for Health and Welfare.
  • Department of Public Health, Faculty of Medicine, University of Helsinki, Finland.
  • Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands.
  • Sanofi Pasteur SA, Lyon, France.
  • Pfizer Limited, NewYork, New York.
  • Department of Pediatrics, University of Turku and Turku University Hospital, Finland.

ORCID-Profile: Eero Poukka, Topi Turunen, Ulrike Baum, Rolf Kramer, Elizabeth Begier, Lance Presser, Anne Teirlinck, Terho Heikkinen

Zitieren

APA

Poukka, E., van Roekel, C., Turunen, T., Baum, U., Kramer, R., Begier, E., Presser, L., Teirlinck, A., Heikkinen, T., Knol, M., Nohynek, H., & PROMISE Investigators (2024). Effectiveness of Vaccines and Monoclonal Antibodies Against Respiratory Syncytial Virus: Generic Protocol for Register-Based Cohort Study. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiad484

Vancouver

Poukka E, van Roekel C, Turunen T, Baum U, Kramer R, Begier E, et al. Effectiveness of Vaccines and Monoclonal Antibodies Against Respiratory Syncytial Virus: Generic Protocol for Register-Based Cohort Study. The Journal of Infectious Diseases. 2024. doi:10.1093/infdis/jiad484

BibTeX
@article{Poukka2024,
  author = {Poukka, Eero and van Roekel, Caren and Turunen, Topi and Baum, Ulrike and Kramer, Rolf and Begier, Elizabeth and Presser, Lance and Teirlinck, Anne and Heikkinen, Terho and Knol, Mirjam and Nohynek, Hanna and PROMISE Investigators, PROMISE Investigators},
  title = {Effectiveness of Vaccines and Monoclonal Antibodies Against Respiratory Syncytial Virus: Generic Protocol for Register-Based Cohort Study},
  journal = {The Journal of Infectious Diseases},
  year = {2024},
  doi = {10.1093/infdis/jiad484}
}
Kostenlos starten →